Investor mix
9 investors on record; lead investors include NGN Capital, Forbion, Qiagen, Arcus Ventures; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 56% |
| Private equity | 1 | 11% |
| Other / undisclosed | 3 | 33% |
Developer of blood-based cancer molecular diagnostics for patient stratification and disease monitoring
9 investors on record; lead investors include NGN Capital, Forbion, Qiagen, Arcus Ventures; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 56% |
| Private equity | 1 | 11% |
| Other / undisclosed | 3 | 33% |